Remdesivir, an anti-viral drug initially developed to treat the Ebola virus, has shown some early promise as a treatment for COVID-19, the disease caused by the novel coronavirus, CNBC reports.
On Wednesday, Remdesivir’s manufacturer, Gilead Sciences, said that a clinical study of the drug as a treatment for the coronavirus showed encouraging results.
Specifically, 397 patients with severe COVID-19 were studied in a “single-arm” study, which is to say, all of the patients in the study received the treatment, and there was no control group of patients who received a placebo, as is normally the case in clinical drug trials.
Rather, the study gave two groups of patients the medicine over a different time periods. One group received the drug over a 5-day period, while the other group received it for 10 days.
0 comments :
Post a Comment